Oct 23, 2019
Join us for part two of our interview with Chief Medical Oncologist at USA Mitchell Cancer Institute, Dr. Arthur Frankel, where we'll be discussing some very interesting statistics about what might be the next big frontier in oncology therapy.
Be sure to check out part one of the interview for a deep dive into oncology and microbiome!
Dr. Arthur Frankel is the Chief Medical Oncologist at USA Mitchell Cancer Institute in Mobile, Alabama where he specializes in Hematology and Medical Oncology. He received his medical degree from Harvard Medical School with his residency and medical oncology fellowship at Stanford University.
Frankel is passionate about helping oncologists and the community navigate the rapid advances in cancer care. He says there is an “explosion of knowledge” that comes with new treatments and his “goal is to advance the quality of cancer care in his area. Having received over a dozen grants, and participated in just as many clinical trials, he currently has a pending grant for 5-year study on the "Role of Gut Microbiota in Modulating Immune Checkpoint Inhibitor Therapy for Cancer." Frankel has stated that immunotherapy is the most important advance in the past decade against cancer. He understands and is passionate about the connection between the immune system and the constantly evolving nature of cancer and tumors.